Johan M Lorenzen1, Nils Nickel2, Robert Krämer3, Heiko Golpon2, Volker Westerkamp2, Karen M Olsson2, Hermann Haller3, Marius M Hoeper2. 1. Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany. Electronic address: J.M.Lorenzen@gmail.com. 2. Department of Respiratory Medicine, Centre of Internal Medicine, Hannover Medical School, Hannover, Germany. 3. Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany.
Abstract
BACKGROUND: Osteopontin (OPN) is a pleiotropic cytokine that has been postulated to play a role in the pathogenesis of idiopathic pulmonary arterial hypertension (IPAH). OPN plasma levels may be related to disease severity and mortality in patients with PAH. METHODS: OPN plasma levels obtained during right-sided heart catheterization were assessed by a commercially available enzyme-linked immunosorbent assay and related to hemodynamics, exercise capacity, N-terminal pro-brain natriuretic peptide (NT-pro-BNP) level, uric acid level, C-reactive protein level, and survival in two cohorts of patients with IPAH: a 4-year retrospective cohort (n = 70) and a prospective cohort (n = 25) followed for 3 months after initiation of therapy. Forty apparently healthy individuals served as control subjects. RESULTS: Baseline OPN levels were elevated in patients with IPAH compared with healthy control subjects (50.2 ± 35.9 vs 23.7 ± 2.8 ng/mL, P < .0001). In the retrospective as well as in the prospective cohort, OPN levels correlated with mean right atrial pressure and NT-BNP. In the retrospective cohort, OPN levels also correlated with age (r = 0.3, P = .02), 6-min walking distance (r=-0.4, P = .05), and New York Heart Association class (r = 0.4, P = .001). Multivariate Cox analysis demonstrated that baseline OPN levels were independent predictors of mortality (P = .02). When patients were divided according to their baseline OPN values, being normal or elevated at baseline (below or above 34.5 ng/mL), proportional survival rates were 100% vs 80% after 1 year and 77% vs 51% after 3 years, respectively. CONCLUSION: Circulating OPN predicts survival in patients with IPAH and is associated with a higher New York Heart Association class. OPN, thus, may be useful as a biomarker in IPAH.
BACKGROUND:Osteopontin (OPN) is a pleiotropic cytokine that has been postulated to play a role in the pathogenesis of idiopathic pulmonary arterial hypertension (IPAH). OPN plasma levels may be related to disease severity and mortality in patients with PAH. METHODS:OPN plasma levels obtained during right-sided heart catheterization were assessed by a commercially available enzyme-linked immunosorbent assay and related to hemodynamics, exercise capacity, N-terminal pro-brain natriuretic peptide (NT-pro-BNP) level, uric acid level, C-reactive protein level, and survival in two cohorts of patients with IPAH: a 4-year retrospective cohort (n = 70) and a prospective cohort (n = 25) followed for 3 months after initiation of therapy. Forty apparently healthy individuals served as control subjects. RESULTS: Baseline OPN levels were elevated in patients with IPAH compared with healthy control subjects (50.2 ± 35.9 vs 23.7 ± 2.8 ng/mL, P < .0001). In the retrospective as well as in the prospective cohort, OPN levels correlated with mean right atrial pressure and NT-BNP. In the retrospective cohort, OPN levels also correlated with age (r = 0.3, P = .02), 6-min walking distance (r=-0.4, P = .05), and New York Heart Association class (r = 0.4, P = .001). Multivariate Cox analysis demonstrated that baseline OPN levels were independent predictors of mortality (P = .02). When patients were divided according to their baseline OPN values, being normal or elevated at baseline (below or above 34.5 ng/mL), proportional survival rates were 100% vs 80% after 1 year and 77% vs 51% after 3 years, respectively. CONCLUSION: Circulating OPN predicts survival in patients with IPAH and is associated with a higher New York Heart Association class. OPN, thus, may be useful as a biomarker in IPAH.
Authors: Joseph M Collaco; Lewis H Romer; Bridget D Stuart; John D Coulson; Allen D Everett; Edward E Lawson; Joel I Brenner; Anna T Brown; Melanie K Nies; Priya Sekar; Lawrence M Nogee; Sharon A McGrath-Morrow Journal: Pediatr Pulmonol Date: 2012-07-06
Authors: Andriy O Samokhin; Steven Hsu; Paul B Yu; Aaron B Waxman; George A Alba; Bradley M Wertheim; C Danielle Hopkins; Frederick Bowman; Richard N Channick; Ivana Nikolic; Mariana Faria-Urbina; Paul M Hassoun; Jane A Leopold; Ryan J Tedford; Corey E Ventetuolo; Peter J Leary; Bradley A Maron Journal: J Heart Lung Transplant Date: 2019-12-31 Impact factor: 10.247
Authors: Adil Anwar; Min Li; Maria G Frid; Binod Kumar; Evgenia V Gerasimovskaya; Suzette R Riddle; B Alexandre McKeon; Roopa Thukaram; Barbara O Meyrick; Mehdi A Fini; Kurt R Stenmark Journal: Am J Physiol Lung Cell Mol Physiol Date: 2012-05-11 Impact factor: 5.464
Authors: Aaron Y Lai; Illsung L Joo; Arunachala U Trivedi; Adrienne Dorr; Mary E Hill; Bojana Stefanovic; JoAnne McLaurin Journal: Brain Res Date: 2021-02-12 Impact factor: 3.252